Exubera taken off market

Pfizer has announced that it will be returning the worldwide rights for Exubera (human insulin) to Nektar, the company from which the inhaled insulin technology was licensed.

The decision to stop marketing Exubera is due to the product falling short of company and customer expectations. Pfizer will support current Exubera patients until 16 January 2008 as they transfer to other glucose-lowering therapies, but after that Exubera will no longer be promoted or sold.


Healthcare professionals should not start any new patients on Exubera. Patients currently using Exubera should be transfered to alternative glucose-lowering medications.

Further information: Pfizer 01304 616161

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more